Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.80 |
| ▸ | MAOB | P27338 | 4/20 | 0.80 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | BCHE | P06276 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.70 |
| ▸ | TFEB | P19484 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5084268 | 0.89 | AR (1.00) | ARMAOBNR1H4ABCG2MAPT | |
| SCHEMBL30807180 | 0.89 | AR (1.00) | ARMAOBNR1H4ABCG2MAPT | |
| SCHEMBL15631497 | 0.89 | ABCG2 (0.68) | ARMAOBNR1H4ABCG2MAPT | |
| SCHEMBL5084274 | 0.89 | AR (1.00) | ARMAOBNR1H4ABCG2MAPT | |
| SCHEMBL1764951 | 0.88 | NFE2L2 (0.70) | ARMAOBNR1H4ABCG2MAPT | |
| SCHEMBL21661955 | 0.88 | AR (0.72) | ARMAOBNR1H4MAPTNPC1 | |
| SCHEMBL7100046 | 0.88 | AR (0.72) | ARMAOBNR1H4ABCG2MAPT | |
| SCHEMBL19423222 | 0.88 | ABCG2 (0.74) | ARMAOBNR1H4ABCG2MAPT | |
| SCHEMBL30194637 | 0.86 | AR (0.66) | ARMAOBNR1H4ABCG2MAPT | |
| SCHEMBL31167606 | 0.86 | ABCG2 (0.77) | ARMAOBNR1H4ABCG2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| CN-118894756-A | Deoxidization and reduction method for alpha, beta unsaturated ketone | 温州医科大学 | 2024-11-05 | — | — | CN | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2024-04-09 | — | — | US | disclosed |
| WO-2023165870-A1 | COMPOSITIONS AND METHODS TO POTENTIATE MUSCULOSKELETAL EFFECT OF ONE OR MORE ANABOLIC AMINO ACIDS ON BONE HEALTH | Société des Produits Nestlé S.A. (CH) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023158383-A2 | METHOD FOR CELLULAR LIFESPAN MEASUREMENT | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-08-24 | — | — | WO | disclosed |
| EP-2810198-B1 | ANTI-INVASIVE COMPOUNDS | UNIV GENT (BE) | 2023-07-12 | — | — | EP | disclosed |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| EP-3986557-A1 | COMPOSITIONS AND METHODS TO POTENTIATE MUSCULOSKELETAL EFFECT OF ONE OR MORE ANABOLIC AMINO ACIDS | Société des Produits Nestlé S.A. (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2022-03-08 | — | — | US | disclosed |
| EP-1781305-A2 | COMPOSITIONS AND METHODS USING HYALURONIC ACID AND HYALURONIDASE INHIBITORS | ANGIOTECH INTERNATIONAL AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| EP-1748767-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | Unigen Pharmaceuticals, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006127539-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006020994-A2 | COMPOSITIONS AND METHODS USING HYALURONIC ACID AND HYLURONIDASE INHIBITORS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005117849-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| EP-0661967-A1 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1995-07-12 | — | — | EP | disclosed |
| EP-0661967-A4 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS. | UNIV VIRGINIA (US) | 1994-09-29 | — | — | EP | disclosed |
| WO-1993009764-A1 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-05-27 | — | — | WO | disclosed |
| US-4863968-A | Methods of treating gout with chalcone derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | HNMT, INMT, TYR | AR 4081/4885MAOB 361/4885NR1H4 4145/4885 |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | MCL1, CD44, INMT | AR 3990/4885MAOB 1982/4885NR1H4 2700/4885 |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | AR 3778/4885MAOB 823/4885NR1H4 4224/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | AR 1367/4885MAOB 1509/4885NR1H4 1209/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | AR 3053/4885MAOB 806/4885NR1H4 2294/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | AR 4232/4885MAOB 2103/4885NR1H4 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.